A large Tulsa orthopaedic practice offering orthobiologic injections using the patient's own tissue, whose own published article takes a notably cautious line on stem cell marketing.
Tulsa Bone and Joint Associates is an established orthopaedic group practice with its main office at 4802 South 109th East Avenue, Tulsa. Its orthobiologics service is presented as one part of a conventional orthopaedic offering rather than as a standalone regenerative medicine business, and it is framed as a non-surgical option for chronic pain.
On the orthobiologics page the practice describes using the body's own natural healing mechanisms, indicating an autologous approach, meaning material taken from the patient themselves. The conditions listed are osteoarthritis and rheumatoid arthritis, cartilage injuries, tennis and golfer's elbow, partial ligament tears including the anterior cruciate, medial collateral and posterior cruciate ligaments, partial tendon tears of the rotator cuff, knee, quadriceps, wrist and hip, plantar fasciitis and tendonitis. The page itself does not spell out which products are used.
A separate article published by the practice is unusually useful for a patient trying to compare options, because it draws a distinction that most clinic websites blur. It describes bone marrow and fat as true orthobiologics, and treats platelet rich plasma (PRP, prepared from the patient's own blood), autologous conditioned plasma (ACP, another preparation from the patient's own blood) and concentrated amniotic fluid as growth factor injections rather than cell therapies. Two of its surgeons are quoted urging caution: Tony Jabbour, MD warns against aggressive marketing in this field, and Keith Stanley, MD emphasises exhausting standard treatments first. The article states that these injections are never a cure for conditions such as arthritis, and notes that it reports on studies rather than making promises.
On cost the practice is explicit where most are silent. The article states that the treatment is not covered by insurance because it is not approved by the United States Food and Drug Administration, and repeats that neither autologous conditioned plasma nor platelet rich plasma is covered by insurance. No actual prices are published, so a patient would need to ask for a figure, but they are at least told clearly to expect to pay privately.
The conditions below are those the practice names on its orthobiologics page.
The practice states that its orthobiologic treatments use the body's own natural healing mechanisms, and in a published article distinguishes bone marrow and fat as true orthobiologics from blood-derived and amniotic growth factor injections.
Two surgeons are quoted in the practice's orthobiologics writing; the service page itself names no injecting clinician.
The practice's main office is at 4802 South 109th East Avenue, Tulsa, and it is one of the larger orthopaedic groups in the city with a wide clinical team and additional locations. Orthobiologic injections are offered as part of general orthopaedic care rather than through a separate cell therapy unit. The pages reviewed do not describe the laboratory or processing arrangements for bone marrow or fat preparations, nor name any accreditation for them.
No prices are published, but the practice is unusually clear about coverage: its article states that the treatment is not covered by insurance because it is not approved by the United States Food and Drug Administration, and that neither autologous conditioned plasma nor platelet rich plasma is covered by insurance. A patient should expect to pay privately and ask the practice for a figure.
Profile compiled from information published on the clinic's own website and from the StemCell Registry directory record. Details may change; confirm directly with the clinic before making decisions.